Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$321.91 USD

321.91
2,654,799

+0.12 (0.04%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Is the Options Market Predicting a Spike in Amgen (AMGN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

FTC Challenges Amgen's (AMGN) $28B Acquisition of Horizon

by Zacks Equity Research

Per the FTC, Amgen's (AMGN) acquisition of Horizon (HZNP) would entrench the monopoly positions for the latter's medications for thyroid eye disease and chronic refractory gout.

Pfizer (PFE) to Raise $31B in Debt to Fund Seagen (SGEN) Deal

by Zacks Equity Research

Pfizer (PFE) offers bonds worth $31 billion to fund its pending acquisition of cancer drugmaker, Seagen (SGEN).

FTC May Reportedly Block Amgen's (AMGN) $28B Horizon Buyout

by Zacks Equity Research

Unconfirmed reports suggest that the FTC may challenge the $28-billion buyout of Horizon Therapeutics (HZNP) by Amgen.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Neena Mishra headshot

Biotech ETFs Pop on M&A Resurgence

by Neena Mishra

2023 could be a year of heightened biotech dealmaking activity

Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Pfizer (PFE) Q1 Earnings Beat, COVID Jab Sales Down as Expected

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q1 earnings and sales. Revenues from its COVID-19 vaccine, Comirnaty declined, as expected.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised

by Zacks Equity Research

Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023.

Amgen (AMGN) Q1 Earnings Beat Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 3.65% and 0.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform

by Zacks Equity Research

AbbVie's (ABBV) first-quarter 2023 earnings and sales beat estimates. However, share price dives as some key drugs miss sales estimates.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Will Humana's (HUM) Q1 Earnings Beat on Insurance Unit Strength?

by Zacks Equity Research

Humana's (HUM) first-quarter results are likely to reflect surging premiums and investment income.

Can Rising Expenses Hurt Teladoc Health's (TDOC) Q1 Earnings?

by Zacks Equity Research

Teladoc Health's (TDOC) first-quarter results are likely to reflect growth in Access Fees revenues and total visits.

Bristol-Myers (BMY) to Report Q1 Earnings: What+'s in Store?

by Zacks Equity Research

Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q1 results.

Can Amgen (AMGN) Keep the Earnings Streak Alive in Q1?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Eli Lilly (LLY) to Report Q1 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Lilly's (LLY) first-quarter sales.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Ekta Bagri headshot

4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates

by Ekta Bagri

We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.